USANA preliminary Q2 net sales ~$265M (down 21% YoY); cuts FY2022 guidance sharply

USANA HEALTH SCIENCES INC

2022-Q2 EPS reported $2.15 revenue$537,341,000

Preliminary Q2 net sales ~$265M vs $337M a year ago; EPS ~$1.05 vs $1.87.
FY2022 guidance cut: net sales now $1.015-1.065B (prev. $1.1-1.2B); EPS $3.85-4.45 (prev. $5.00-5.70).
COVID lockdowns in China and regional sales program disruption drove weaker Q2 results.
CEO Kevin Guest cites lower program participation and inflationary pressures; final Q2 results due July 26.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.